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Abstract
BACKGROUND & AIMS—Esophageal adenocarcinoma (EA) is increasingly common among 
patients with Barrett’s esophagus (BE). We aimed to provide consensus recommendations based 
on the medical literature that clinicians could use to manage patients with BE and low-grade 
dysplasia, high-grade dysplasia (HGD), or early-stage EA.
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METHODS—We performed an international, multidisciplinary, systematic, evidence-based 
review of different management strategies for patients with BE and dysplasia or early-stage EA. 
We used a Delphi process to develop consensus statements. The results of literature searches were 
screened using a unique, interactive, Web-based data-sifting platform; we used 11,904 papers to 
inform the choice of statements selected. An a priori threshold of 80% agreement was used to 
establish consensus for each statement.
RESULTS—Eighty-one of the 91 statements achieved consensus despite generally low quality of 
evidence, including 8 clinical statements: (1) specimens from endoscopic resection are better than 
biopsies for staging lesions, (2) it is important to carefully map the size of the dysplastic areas, (3) 
patients that receive ablative or surgical therapy require endoscopic follow-up, (4) high-resolution 
endoscopy is necessary for accurate diagnosis, (5) endoscopic therapy for HGD is preferred to 
surveillance, (6) endoscopic therapy for HGD is preferred to surgery, (7) the combination of 
endoscopic resection and radiofrequency ablation is the most effective therapy, and (8) after 
endoscopic removal of lesions from patients with HGD, all areas of BE should be ablated.
CONCLUSIONS—We developed a data-sifting platform and used the Delphi process to create 
evidence-based consensus statements for the management of patients with BE and early-stage EA. 
This approach identified important clinical features of the diseases and areas for future studies.
Keywords
BADCAT; Esophageal Cancer; Treatment Strategy; Systematic Analysis
Barrett’s esophagus (BE) is defined as the replacement of distal esophageal squamous 
mucosa with metaplastic columnar epithelium.1 It occurs in 4% of patients undergoing an 
upper gastrointestinal endoscopy, and in 9% of men over 50 years of age.2 BE is more 
common in developed countries, affecting 2% of the population, because it is strongly 
associated with gastroesophageal re-flux disease3,4 and this disease incidence is increasing 
in developing countries.5 The main concern with BE is the associated increased risk for 
esophageal adenocarcinoma (EA). EA is the fastest growing cause of cancer mortality,6 and 
it is estimated that patients with BE have at least a 20-fold increased risk of developing 
EA.7–9 Most guidelines10,11 recommend surveillance endoscopy every 2 to 5 years in 
patients with BE to detect early, treatable neoplasia and early signs of high-grade dysplasia 
(HGD). If progression to low-grade dysplasia (LGD), HGD, or EA can be detected early in 
its course, cancer can either be prevented or treated at a curable stage.12,13
There is a lack of agreement concerning optimal management of dysplasia and early EA 
and, therefore, management practice patterns vary considerably among BE experts. The 
classification and recognition of dysplasia, both by endoscopy and histology, are variable 
among and within countries, and between some medical centers. There remains 
heterogeneity in the management of HGD/early EA throughout the world; the primary 
alternatives include managing HGD with surveillance alone, endoscopic therapy to remove 
HGD or early EA, or surgical resection of the BE (esophagectomy).14 Innovations have 
taken place in the endoscopic management of EA.15 In this rapidly changing field, a rational 
consensus approach to BE patients with LGD, HGD, and early EA is necessary to help 
inform the practicing clinician. Previously, several consensus papers have had some impact 
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on clinical management1,10 but have focused on BE in general; the focus of this guideline is 
LGD, HGD, and early EA.
Methods
The specific population under consideration consisted of adults aged 18 years or older with a 
diagnosis of BE plus LGD, HGD, or early EA, the latter being defined as intramucosal EA 
(T1m) or superficial submucosal EA (T1sm1). We used a Delphi process to develop 
consensus statements for LGD/HGD/early EA. This approach combines the principles of 
evidence-based medicine supported by systematic literature reviews with the use of an 
iterative anonymous voting process. This software program permitted anonymous individual 
feedback and changes of views during the process, together with controlled feedback of 
evidence regulated by the coordinator (CB) and the consensus chair (JJ). The Delphi 
process16 is now increasingly used in health care as a rigorous means of determining 
consensus in a defined clinical area1,17 and is reliable.18
The principal steps in the process were: (1) selection of the consensus group; (2) 
development of draft statements by panels; (3) systematic literature reviews to identify 
evidence to support each statement (search key words, Appendix 1); (4) 4 rounds of repeated 
anonymous voting on iterations of the statements (with feedback at each round) until 
consensus was reached (Appendix 2) (Figure 1); and (5) grading of the strength and quality 
of the evidence and strength of the recommendations using accepted criteria19,20 (Appendix 
2). Details are listed in Appendix 3.21
Results
The initial stage was development of statements followed by a comprehensive literature 
review. Eventually, 4 in-person meetings followed by 4 rounds of consensus voting resulted 
in consensus (80% of respondents strongly agree or agree with reservation) being achieved 
in 81 of 91 statements. The respondents were asked to choose 1 of the following for each 
statement; agree strongly (A+), agree with reservation (A), undecided (U), disagree (D) or 
disagree strongly (D+). Although evidence-based explanations with key references were 
provided when relevant, it was the statement on which people voted. Consistent with 
principles of the Delphi process,19 the level of agreement increased with each round of 
voting (Figure 1). This high level of consensus was also exemplified by a post hoc analysis, 
where if >50% of respondents strongly agreed with the statement, it was accepted as a 
measure of agreement (Figure 1). Overall, the proportion of participants voting for each 
statement increased with each round of voting.
We selected 20 statements that represent the following key clinically relevant areas: 
diagnosis, epidemiology, methods of surveillance, approaches to treatment, and prevention 
of HGD and early adenocarcinoma in patients with BE. A description of any concerns about 
the statement is provided from the online comments of the respondents. We focused on 
HGD and early EA, as this area has the most evidence. All the remaining statements are 
outlined in Appendix 2.
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Diagnosis of BE and HGD
Histologically, there is poor inter-observer agreement among pathologists in 
distinguishing HGD from intra-mucosal adenocarcinoma
Agreement: A+ 62%, A 33%, U 4%, D 1%, D+ 0%. Evidence: Moderate: The extent 
and severity of the dysplastic changes distinguishes HGD from LGD.22 Expert pathologists 
have found distinguishing HGD from intramucosal EA remains problematic.23 The widely 
accepted definition of intramucosal EA is a lesion in which neoplastic cells have penetrated 
the basement membrane and invaded the lamina propria, but have not yet penetrated through 
the muscularis mucosae. However, reliable histologic recognition of lamina propria invasion 
is difficult due to the absence of objective and validated criteria. Kappa statistics for 
distinguishing between HGD and intramucosal EA vary between 0.21 and 0.47, suggesting 
poor, or at best, fair agreement.23–25
At least 2 experienced gastrointestinal pathologists should evaluate all 
Barrett’s biopsies when a diagnosis of dysplasia is considered
Agreement: A+ 79%, A 15%, U 4%, D 1%, D+ 1%. Evidence: Moderate: It has long 
been recognized that there is inter-observer variability between pathologists in 
differentiating HGD from intramucosal EA as described here. Five studies26–30 have shown 
that the prediction of progression of esophageal dysplasia is improved if at least 2 expert 
pathologists agree on a diagnosis of dysplasia, and increases when more pathologists concur 
with the diagnosis.27,29,30
Risk of Progression to Esophageal Adenocarcinoma
Non-goblet columnar metaplasia of the esophagus can progress to cancer, 
but the magnitude of risk is unknown
Agreement: A+ 59%, A 33%, U 6%, D 2%, D+ 0%. Evidence: Low: The US definition 
of BE requires that intestinal metaplasia is present in the salmon-colored esophageal 
columnar-lined mucosa of the tubular esophagus. There is, however, evidence that non-
goblet columnar metaplasia of the distal esophagus shows biological features of intestinal 
differentiation, and possesses molecular abnormalities consistent with a risk of malignancy 
of neoplasia precursor lesions.31–34 Two retrospective studies35,36 evaluated the risk of 
neoplasia in patients with columnar metaplasia of the esophagus either with or without 
goblet cells. There were 991 patients with intestinal metaplasia and 631 without intestinal 
metaplasia. The incidence of cancer progression from BE was similar in the 2 patient groups 
(4.5% vs 3.6% in one study35 and 3.1% vs 3.2% in the other36). Non-goblet cell columnar 
metaplasia has malignant potential, although the relative risk is unclear.
Extent of dysplasia can correlate with progression to cancer in BE
Agreement: A+ 52%, A 44%, U 4%, D+ 0%, D 0%; Evidence: Very low: The majority 
of participants agreed with this statement and 3 articles have evaluated whether the extent of 
dysplasia is a risk factor for EA in BE.37–39 Two studies37,38 (total of 177 patients) 
concluded that the extent of dysplasia was correlated with the risk of progression.37,38 
However, one retrospective study39 of 42 patients from a pathology database with BE and 
HGD who underwent esophagectomy failed to show a significant association between extent 
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of dysplasia and the risk of malignancy. Each of the 3 studies used different criteria and 
definitions for dysplasia.
Ulcers in BE that fail to heal with proton pump inhibitor therapy are a very 
suspicious finding and should be monitored closely for development of 
carcinoma
Agreement: A+ 66%, A 24%, U 10%, D 0%, D+ 0%. Evidence: Very 
low: Unfortunately, there are no good case series on ulcerating lesions in BE that do not heal 
with proton pump inhibitor therapy,40 although experts would suggest that BE-related ulcers 
are associated with malignancy.
Visible lumps or nodules consisting of HGD suggest a more advanced lesion 
with invasion might be present
Agreement: A+ 73%, A 26%, U 1%, D 0%, D+ 0%. Evidence: Low: Endoscopic 
mucosal resection (EMR/ER) of visible lumps with HGD on endoscopic biopsy results in 
upgrading the final diagnosis to cancer in 40% of cases.41,42 In a series of esophagectomies 
performed for presumed HGD identified by endoscopic biopsies, coexisting EA was found 
in 7 of 9 patients (78%) with a visible lesion and 7 of 22 patients (32%) without a visible 
lesion (P = .02).43
Risk of progression from HGD to EA is approximately 10% per year (range 
6%–19%)
Agreement: A+ 45%, A 40%, U 5%, D 6%, D+ 4%. Evidence: Low: This statement 
achieved consensus based on a systematic review,44 which identified 4 studies45–48 
involving 236 BE patients with HGD that suggested a conversion rate of 6% per year, 
contrasting with a large randomized controlled trial demonstrating conversion from HGD to 
EA of 19% in 1 year.49 This risk estimate assumes that no endoscopic or surgical 
intervention takes place and that there are no macroscopically visible lesions. The issue of 
concomitant EA in patients who are diagnosed with BE and HGD is another consideration. 
In the absence of visible lesions in BE, the prevalence of EA in patients who underwent 
esophagectomy was 3%.50,51
Methods of Surveillance for Patients With BE and With HGD
For evaluation of patients with BE, the use of high-resolution endoscopes and 
targeted biopsies of every suspicious lesion followed by 4-quadrant biopsies 
every 1–2 cm are recommended
Agreement: A+ 60%, A 38%, U 1%, D 0%, D+ 1%. Evidence: Very low: A high-
resolution endoscope (>850,000 pixels) should be used to evaluate patients with BE. 
Standard-resolution endoscopes are not recommended, although there is scant scientific 
evidence for this recommendation. Evidence that greater resolution improves diagnosis is 
only available and supports narrow band imaging,52 but for chromoendoscopy there was no 
superiority to chromoendoscopy over standard endoscopy, although acetic acid spraying can 
improve visualization of lesions.53,54 Even with high-resolution endoscopes, 4-quadrant 
biopsies are still necessary after careful evaluation of the BE segment to exclude 
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synchronous neoplastic lesions. They should be performed with 4 biopsies at 1–2-cm 
intervals throughout the entire BE segment. There are no data demonstrating superiority of 
1-cm intervals compared with 2-cm intervals.55,56
Treatment of HGD and Early EA
Endoscopic treatment should be preferred over endoscopic surveillance for 
management of most BE patients with HGD/T1m Barrett’s esophagus
Agreement: A+ 78%, A 19%, U 4%, D 0%, D+ 0%. Evidence: Moderate: There was 
strong agreement with this statement among the group. It is difficult to exclude EA 
complicating HGD based on biopsies only. Endoscopic surveillance can lead to under-
diagnosis of cancer at baseline, especially when HGD is located in the area of BE that is 
endoscopically unremarkable.23,42 Endoscopic therapy (initially EMR for visible lesions) 
aimed at removing all BE mucosa should treat all areas of HGD and early EA that might 
have been missed by surveillance alone. Two randomized sham-controlled studies46,49 of 
ablation therapy (after initial EMR where appropriate) vs endoscopic surveillance have 
shown a significantly higher progression rate to cancer in the surveillance arm. Endoscopic 
treatment can cause complete remission of neoplasia in 80%–100% of cases and complete 
removal of BE with intestinal metaplasia in >75% of cases.40,49,57–60 Severe complications 
(such as bleeding, perforation, or stricture) are uncommon.40,49,57–60
For patients with HGD in an endoscopically visible abnormality, endoscopic 
resection is essential for proper diagnosis and staging
Agreement: A+ 79%, A 16%, U 3%, D 1%, D+ 1%. Evidence: Moderate: EMR can 
lead to a significant change in diagnosis compared with a previous biopsy diagnosis.42,61–63 
EMR provides a larger tissue specimen that is generally better orientated, allowing easier 
interpretation by pathologists.62 In addition, when an area of HGD is endoscopically visible, 
it is more likely to harbor EA.42,63,64 If EA is found in the EMR specimen, the risk of local 
lymph node metastasis has been shown to correlate with the depth of invasion,65,66 allowing 
better selection of therapy.67,68
Endoscopic treatment should be preferred over surgical treatment for 
management of most patients with HGD in BE
Agreement: A+ 64%, A 29%, U 3%, D 2%, D+ 2%. Evidence: Low: There was strong 
consensus for this approach. HGD in BE is rarely associated with lymph node involvement, 
provided that deeper invasion has been ruled out by EMR (as described in statement 
10).57,58,69,70 Two case series40,57,58 reported that survival after EMR was high, similar to 
that expected in a surgical cohort. One cohort study71 reported that the disease-specific 
survival rate after endoscopic treatment was not different from surgical therapy. The case 
series reported a lower morbidity than might be expected in surgical patients.40,57,58 
Endoscopic treatment is associated with a higher rate of HGD recurrence,40,57,58,71 although 
this can usually be treated endoscopically.40,57,58,72 Finally, on the rare occasion that 
endoscopic treatment fails, surgical resection is still possible and generally curative.40,57,58
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Widespread EMR can cause strictures (especially when more than two thirds 
of the circumference is removed)
Agreement: A+ 74%, A 21%, U 4%, D 1%, D+ 0%. Evidence: Low: The intention of 
EMR/ER) should be to remove all visible dysplasia. It should ideally be restricted to less 
than two thirds of the esophageal circumference in order to reduce the risk of strictures, but 
all visible lesions should be resected. Strictures resulting from EMR respond well to 
dilation.73–75
Endoscopic treatment of HGD/T1m should only be performed in tertiary 
referral care centers after proper training of the endoscopists and 
pathologists involved
Agreement: A+ 57.5%, A 34%, U 2.5%, D 6%, D+ 0%. Evidence: Very low: There are 
no studies that have shown that centers with expertise, or those that have high case volumes, 
provide better quality care for BE patients with HGD/early EA. The consensus group voted 
positively for this statement because in other areas of gastroenterology, expertise and case 
volumes are associated with better outcomes.76,77 Adequate management of these patients 
encompasses a wide range of experience, equipment, and a certain case volume (which we 
arbitrarily defined as >10 cases per year).78–82
After EMR has removed visible lesions with HGD/T1m, the remaining BE 
segment should be eradicated regardless of whether or not it includes the 
presence or absence of dysplasia
Agreement: A+ 54%, A 30%, U 13%, D 3%, D+ 0%. Evidence: Very low: Statement 10 
recommended EMR for visible abnormalities with HGD. If EMR is the only modality that is 
used and the remaining BE mucosa is left untreated, case series have reported recurrence of 
neoplasia. Rates vary from 11% to 30% (mean follow-up of 3 years).57,83 Ablation of the 
remaining BE is associated with a lower recurrence rate.40,49,59,60,84,85
Radiofrequency ablation is currently the best available ablation technique for 
treatment of flat HGD and for eradication of residual BE mucosa after focal 
EMR
Agreement: A+ 59%, A 25%, U 11%, D 1%, D+ 4%. Evidence: Low: Statement 14 
recommended endoscopic ablation of BE after EMR for visible lesions. The question 
remains, what is the most appropriate endoscopic technique? The alternatives that have been 
most frequently studied include photodynamic therapy, radiofrequency ablation (RFA), 
and/or stepwise EMR of all BE. A systematic review86 of photodynamic therapy for HGD of 
BE mucosa esophagus suggests that this approach reduces the risk of progression to cancer 
compared with surveillance alone.46,87 However, complications remain a problem with this 
technique,46 and HGD dysplasia persists in 33%–50% of patients.87,88 Other therapeutic 
modalities include cryotherapy and argon plasma coagulation. Cryotherapy has not been 
evaluated in randomized controlled trials and argon plasma coagulations has only been 
reported in small randomized controlled trials, although there are anecdotal high-success 
rates.89 One systematic review90 suggests that success rates with RFA are superior, with 
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approximately 90% of patients having no HGD after therapy and this seems to be 
maintained.49,59,91–93
In patients with superficial submucosal cancer in BE and low-risk 
characteristics (invasion <500 μm; G1–G2 cancers, no lymph–vascular 
invasion), endoscopic treatment is a valid alternative to esophagectomy
Agreement: A+ 41%, A 35%, U 8%, D 11%, D+ 5%. Evidence: Very low: This 
statement failed to achieve consensus. The paradigm comes from studies from Japan on 
early gastric cancer, which have shown that well to moderately differentiated cancers that 
invade into the submucosa <500 μm and have no lymphovascular invasion, have virtually no 
risk of lymph node metastases.94 Furthermore, in a prospective series of 21 BE patients 
meeting these low-risk criteria,95 no lymph node metastases were found in any of the 
patients after a median follow-up period of 62 months. The implications of lymph node 
spread are so important that more data are needed before this statement can be supported.
Successful surgery/intervention for early cancer can be determined by long-
term (5 years or longer) survival
Agreement: A+ 73%, A 23%, U 3%, D 1%, D+ 0%. Evidence: Very low: The group 
reached consensus that successful surgery is determined by 5-year survival. However, most 
patients with HGD should receive EMR and/or RFA because it is safer and carries a similar 
efficacy rate,96 although more studies are needed (see statements 11, 14, and 15). Surgery is 
still considered the treatment of choice for early EA that has extended into the 
submucosa.97,98 Case series suggest that the 5-year survival rates range from 80% to 
90%.99,100
Reported operative mortality rate for esophagectomy for HGD and T1m 
generally ranges from 0% to 4%, with a mean overall operative mortality of 2%
Agreement: A+ 65%, A 30%, U 3%, D 1%, D+ 1%. Evidence: Very low: Operative 
mortality for patients undergoing esophagectomy for HGD or early EA is difficult to 
generalize because data are primarily from self-selected high-volume centers and analysis is 
retrospective. We identified 10 case series71,98,101–108 evaluating a total of 567 HGD or 
early EA patients (Table 1). Operative mortality rate for esophagectomy for HGD and early 
EA ranges from 0% to 4%, with an overall operative 30-day mortality rate of approximately 
2%.101
Operative mortality is improved if surgery is undertaken in specialist surgical 
centers
Agreement: A+ 90%, A 8%, U 2%, D 0%, D+ 0%. Evidence: Moderate: In contrast to 
the evidence for endoscopic therapy (statement 13), there are good observational data to 
support the performance of esophageal surgery in specialist centers for treatment of EA. 
Results for individual surgeons improve with experience109 and patient outcomes have 
consistently been shown to be better in high-volume centers.110–113
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After eradication of HGD by endoscopic therapy or surgery, endoscopic 
follow-up is required
Agreement: A+ 72.5%, A 20%, U 5%, D 0%, D+ 2.5%. Evidence: Very low: There are 
2114,115 surgical follow-up series involving 57 BE patients that support this statement. Both 
studies report that new BE occur occurs after curative subtotal esophagectomy with gastric 
conduit reconstruction for either EA, squamous cell carcinoma, or HGD.114,115 
Development of BE occurs in half of patients studied114,115 and can recur from 6 months or 
less after surgery114 to 10 years after surgery.115,115 The risk of developing dysplasia or 
malignancy in the “neosquamous” epithelium is unknown, but goblet cells are detected with 
increasing frequency as follow-up continues.115 Based on available evidence, a suggested 
strategy for post-esophagectomy surveillance is to perform screening endoscopy at 2, 5, and 
10 years after surgery. If the risk of dysplasia is assumed to be similar to patients with de 
novo BE, it is reasonable to recommend every 2-year surveillance endoscopies once BE has 
been detected.116 The surveillance interval for patients that have BE ablated with RFA is 
unclear, but a 5-year follow-up study evaluated patients every 2.5 years without any 
recurrence of dysplasia and a low recurrence of BE.91
Discussion
We focused on statements concerning HGD and EA as evidence relating to LGD is 
particularly weak. The management of HGD and EA of the esophagus is heterogeneous and 
the clinician’s perception of the available evidence is one major determinant of this variation 
in practice. The relatively poor quality of data relating to dysplasia in BE is emphasized by 
46 statements having a very low or low level and 38 having moderate or high levels of 
evidence. However, in many cases, it is unlikely that large, well-designed randomized trials 
will ever be done and in this information vacuum there is a need for an authoritative 
consensus on areas where there is good agreement. Our multidisciplinary international group 
has developed consensus to help the practicing clinician with the diagnosis and management 
of HGD and early EA in BE. We focused on patient populations with high-risk disease 
rather than including those statements about LGD, a condition for which there are even less 
objective data in the literature.
The literature search technique used for this consensus process was unique in a number of 
ways. It was much more inclusive than more focused searches, and permitted inclusion of 
additional articles during the consensus process that might have been missed during initial 
searches. Before including articles for citation, the articles were reviewed by panel members 
and a panel chair and were ultimately reviewed and graded by a single senior author, 
resulting in consistency in assessment of the evidence. This mechanism resulted in the 
largest number of articles ever captured in a literature review for gastrointestinal diseases. 
We found that the overall quality of evidence related to the statements was low.
The consensus process resulted in a high level of consensus for most statements, which 
suggests that many results are appropriate for clinical application at this time. The 
relationship of highly relevant clinically applicable consensus findings regarding EMR is 
appreciable. First, EMR provides better staging for visible lesions than do biopsies alone. 
Second, careful mapping of the size of the dysplastic areas by EMR is important to assess 
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the prognosis and risk of progression. Third, EMR combined with RFA is the most proven 
ablative therapy for visible HGD and for ablation of BE in patients with HGD (Figure 2). 
HGD should be managed by RFA with or without EMR, and surgery can be considered for 
early EA.
In defining early cancer, we chose T1sm1 as being the extent of early cancer, as beyond this 
point metastases increases from ~1% to >10% for T1sm2. Including T1sm1 could be 
controversial, but if low-risk sm1 (differentiation grades 1 and 2, without lymphovascular 
invasion and with a negative deep resection margin) tumors are selected, they might be more 
amenable to successful endoscopic therapy. We recognize that evidence from larger series is 
still required to conclude that sm1 are to be considered amenable to endoscopic therapy. 
Using a multidisciplinary approach, surgical treatment should still be considered for early 
cancer (as opposed to HGD) for all patients fit for surgery.
The consensus process also identified several areas where urgent research is needed 
(Appendix 2), including evaluation of genetic markers to determine cancer risk.117,118 
Determining the true risk of progression from dysplasia to EA has implications in term of 
the cost effectiveness of surveillance strategies and impacts on the provision of effective 
treatments. There are no randomized controlled trials, but large epidemiology studies119 –121 
and one meta-analysis122 have reinforced the low conversion rate to cancer for nondysplastic 
Barrett’s123,124 and short Barrett’s.120,121
There are a number of potential shortcomings of this study. First, some geographical areas 
were under-represented. We did not use meta-analysis techniques in a more rigorous 
approach to evaluating the literature, as we believed that the relevant literature was relatively 
scant in quality (even though 11,000 articles were assessed) and diverse in approaches and 
reporting styles, both of which would have severely limited the applicability of these 
techniques to our process. Finally, a template was not used to standardize comments for 
statements, which might have resulted in some unevenness in the presentation of clinical 
view points.
This work represents the most far-reaching, inclusive, and informative consensus process on 
evaluation and management of BE with HGD/early cancer published to date. Most of the 
findings are clinically relevant and the high degree of consensus achieved for most of the 
questions indicates that many of the statements are appropriate for immediate use in guiding 
clinical activity. In addition, areas in which consensus was not achieved are identified, 
helping to guide areas in which future clinical research is likely to be productive (Table 2).
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Proportion of statements achieving consensus with each round of voting. With each round 
voting improved with iterative changes to the question and supporting evidence.
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Management of HGD and/or mucosal cancer (stage T1m) in BE. This consensus has allowed 
the development of a care pathway for HGD and early adenocarcinoma.
BENNETT et al. Page 21

























BENNETT et al. Page 22
Table 1
Operative Mortality for Surgical Series in Patients With HGD or Early EA With BE
First author Year HGD T1m Operative mortality
Tseng101 2003 60 0 1
Reed102 2005 49 0 1
Chang103 2006 9 16 0
Rice104 2006 111 0 0
Moraca105 2006 23 1 0
Peyre106 2007 24 85 7
Williams107 2007 38 0 0
Prasad98 2007 70 0 1
Mirnezami108 2009 23 0 0
Prasad71 2009 0 46 1
407 160 11/567 (1.9%)
Mean operative mortality is 2%.
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Table 2
Areas Ready to Be Applied to Clinical Management
Pathology
1 At least 2 experienced gastrointestinal pathologists should evaluate all Barrett’s biopsies when a diagnosis of dysplasia is 
considered.
Endoscopy
1 The Prague C&Ma Criteria is the best available tool for grading the endoscopic extent of BE.
2 Visible lumps in nodules consisting of HGD suggest a more advanced lesion with invasion might be present.
Populations at risk
1 Men have approximately twice the rate of developing HGD or esophageal cancer compared with women, and the rate at which 
EA is increasing in Western populations is twice as high in men as it is in women.
2 Non-Hispanic white patients with BE are at higher risk for development of HGD/cancer compared with other racial/ethnic groups 
with BE.
3 Obesity is an independent risk factor for development of EA.
Therapy
1 Endoscopic treatment should be preferred over endoscopic surveillance for management of most patients with HGD/T1m BE.
2 RFA is currently the best available ablation technique for treatment of flat HGD and for eradication of residual BE after focal 
EMR.
3 The operative mortality is improved if surgery is undertaken in specialist surgical centers.
NOTE. Several areas that can be applied to clinical practice now include use of Prague Criteria, recognition of subtle masses and use of ER to stage 
lesions.
a
C, circumferential length, M, maximal length.
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